Predictive biomarkers for dasatinib treatment in melanoma.

Eustace, Alex J; Kennedy, Susan; Larkin, Anne-Marie; Mahgoub, Thamir; Tryfonopoulos, Dimitrios; O'Driscoll, Lorraine; Clynes, Martin; Crown, John; O'Donovan, Norma

Eustace, Alex J; Kennedy, Susan; Larkin, Anne-Marie; Mahgoub, Thamir; Tryfonopoulos, Dimitrios; O'Driscoll, Lorraine; Clynes, Martin; Crown, John; O'Donovan, Norma.

Afiliação

Eustace AJ; National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland.
Kennedy S; Research Foundation, Royal Victoria Eye and Ear Foundation, Royal Victoria Eye and Ear Hospital.
Larkin AM; National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland.
Mahgoub T; National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland ; Department of Medical Oncology, St Vincent's University Hospital, Dublin 4, Ireland.
Tryfonopoulos D; National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland ; Department of Medical Oncology, St Vincent's University Hospital, Dublin 4, Ireland.
O'Driscoll L; School of Pharmacy & Pharmaceutical Sciences, Trinity College Dublin, Dublin 2, Ireland.
Clynes M; National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland.
Crown J; National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland ; Department of Medical Oncology, St Vincent's University Hospital, Dublin 4, Ireland.
O'Donovan N; National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland.

Oncoscience ; 1(2): 158-66, 2014.

Article em En | MEDLINE | ID: mdl-25594008

Palavras-chave

ANXA1; CAV-1; EphA2; Melanoma; biomarker; dasatinib

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2014 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google